Sales of Humira rose 20 percent to $1.3 billion; the company said the impact of J&J's launch of Simponi was modest. Forbes noted that Credit Suisse doesn't believe Humira will reach Abbott's goal of $9 billion a year.
Depakote followed the usual trajectory of drugs facing generic competition: Sales plunged 80 percent.
But look at Niaspan, the little cholesterol drug that could: sales were up 6.9 percent to $208 million. That success was probably not affected by news that a trial of Niaspan v. Merck's Zetia was halted for unexplained reasons. Some have speculated that the trial showed an insurmountable benefit of Niaspan, and thus patients in the Zetia arm were switched out of it. It will be interesting to see if that effect is more pronounced in Q3.
Lastly, here's a graph of Abbott's yield in revenues per $1 spent on sales and marketing. Note how lumpy it is. If there's a trend in Abbott's operational efficiency, I ain't seeing it.
- UPDATED: Why Zetia Researchers' Silence on Ending of Niaspan Trial Is Unfair to Merck
- Why Abbott Is Allowed to Manipulate GSK and BMS's AIDS Drug Prices
- Abbott Labs Q1: Has the Company Taken Its Eye Off the Sales Force Ball?
- Abbott Labs' Secret Weapon: Layoffs
- Abbott Labs' "Position of Strength" May Not Be as Strong as It Looks